In 2025, Lilly's Ricks made the most of the big pharma CEOs.
His nearly $6.9M bonus could buy 1,200 - 3,600 Americans Zepbound for a year on TrumpRx (depending on dose).
His $748M in Lilly stock (his total holdings not annual award) could treat 140,000 to 210,000 Americans a year with Zepbound.
For the first time in four years, Endpoints News is raising the bar for what it means to be a top-paid CEO. The previous floor of $20 million is no ...
